Table 1 Characteristics of included studies
Authors (Ref) | Publication year | Sample size (control/intervention) | Population/Country | Intervention (name and daily dose) | Duration | Presented data | Age (y) (control, intervention) |
|---|---|---|---|---|---|---|---|
Arzola-Paniagua (a) et al. [18] | 2016 | 24/15 | Obesity/Mexico | Resveratrlol 300 mg | 24 weeks | TG | 33.7 ± 11.9, 38.8 ± 9.59 |
Arzola-Paniagua (b) et al. [18] | 2016 | 21/24 | Obesity/Mexico | Resveratrlol 300 mg | 24 weeks | TG | 40.96 ± 10.0, 39.76 ± 8.91 |
Bashmakov YK et al. [19] | 2014 | 10/14 | T2DM/Egypt | Resveratrol 100 mg | 2 months | HDL-C, LDL-C, and TC | 54 ± 10.1, 59.8 ± 6.6 |
Bhatt JK et al. [20] | 2012 | 29/28 | T2DM/India | Resveratrol 250 mg | 3 months | TG, HDL-C, LDL-C, and TC | 56.67 ± 8.91, 57.75 ± 8.71 |
Goh KP et al. [21] | 2014 | 5/5 | T2DM/Singapore | Resveratrol 3000 mg | 12 weeks | TG, HDL-C, LDL-C, and ALT | 55.8 ± 7.3, 56.8 ± 5.3 |
Imamura H et al. [22] | 2017 | 25/25 | T2DM/Japan | Resveratrol 100 mg | 12 weeks | TG, HDL-C, TC | 57.4 ± 10.6, 58.2 ± 10.1 |
Zare Javid A et al. [23] | 2017 | 22/21 | T2DM/Iran | Resveratrol 480 mg | 4 weeks | TG | 49.1 ± 7.4, 50.9 ± 8.9 |
Kjær TN et al. [24] (a) | 2017 | 12/21 | MetS/Denmark | Resveratrol 150 mg | 16 weeks | TG, HDL-C, LDL-C, TC, and ALT | 49.1 ± 6.69, 47.8 ± 6.36 |
Kjær TN et al. [24] (b) | 2017 | 12/21 | MetS/Denmark | Resveratrol 1000 mg | 16 weeks | TG, HDL-C, LDL-C, TC, and ALT | 51.9 ± 5.86, 47.8 ± 6.36 |
Kumar BJ et al. [25] | 2013 | 29/28 | T2DM/India | Resveratrol 250 mg | 6 months | TG, HDL-C, LDL-C, and TC | 56.67 ± 8.91, 57.75 ± 8.71 |
Militaru C et al. [26] (a) | 2013 | 29/29 | Stable angina/Romania | Resveratrol 20 mg | 2 months | TG, HDL-C, LDL-C, and TC | 64.9 ± 5.8, 64.2 ± 7.1 |
Militaru C et al. [26] (b) | 2013 | 29/29 | Stable angina/Romania | Resveratrol 20 mg | 2 months | TG, HDL-C, LDL-C, and TC | 66.3 ± 5.5, 63.7 ± 6.2 |
Most J et al. [27] | 2016 | 20/18 | Obese/Netherlands | Resveratrol 80 mg + 282 mg epigallocatechin-3-gallate | 12 weeks | TG, HDL-C, LDL-C, and TC | 36.1 ± 9.33, 38.7 ± 9.83 |
Movahed A et al. [28] | 2013 | 31/33 | T2DM/Iran | Resveratrol 1000 mg | 45 days | TG, HDL-C, LDL-C, TC, ALT,AST, and GGT | 52.45 ± 6.18, 51.81 ± 6.99 |
Poulsen MM et al. [29] | 2013 | 12/12 | Obese/ Denmark | Resveratrol 1500 mg | 4 weeks | TG, HDL-C, LDL-C, TC, and ALT | 44.7 ± 12.12, 31.9 ± 10.03 |
Seyyedebrahimi S et al. [30] | 2018 | 23/23 | T2DM/ Iran | Resveratrol 800 mg | 2 months | TG, HDL-C, LDL-C, TC, ALT, and AST | 54.96 ± 6.37, 58.72 ± 6.06 |
Méndez-del Villar M et al. [31] | 2014 | 10/11 | MetS/ Mexico | Resveratrol 1500 mg | 3 months | TG, HDL-C, LDL-C, and TC | 39.8 ± 5.4, 40.3 ± 5.4 |
Witte AV et al. [32] | 2014 | 23/23 | Overweight subjects/Germany | Resveratrol 200 mg | 26 weeks | TG and TC | 64.8 ± 6.8, 63.7 ± 5.3 |
Chachay VS et al. [33] | 2014 | 10/10 | NAFLD/Australia | Resveratrol 3000 mg | 8 weeks | TG, HDL-C, LDL-C, TC, ALT, and AST | 48.8 ± 12.2, 47.5 ± 11.2 |
Chen S et al. [34] | 2015 | 30/30 | NAFLD/China | Resveratrol 300 mg | 12 weeks | TG, HDL-C, LDL-C, TC, ALT, AST, and GGT | 45.2 ± 10.0, 43.5 ± 11.0 |
Faghihzadeh F et al. [35] | 2015 | 25/25 | NAFLD/Iran | Resveratrol 500 mg | 12 weeks | TG, HDL-C, LDL-C, TC, ALT, AST, and GGT | 44.04 ± 10.10, 46.28 ± 9.52 |
Kantartzis K et al. [36] | 2018 | 52/53 | Overweight and insulin resistant Subjects/Germany | Resveratrol 150 mg | 12 weeks | TG, HDL-C, LDL-C, TC, ALT, AST, and GGT | 18–70 |
Most J et al. [37] | 2018 | 14/11 | Obesity/Netherlands | Resveratrol 80 mg + 282 mg epigallocatechin-3-gallate | 12 weeks | TG | 36 ± 3, 40 ± 3 |
Khodabandehloo H et al. [38] | 2018 | 20/25 | T2DM/Iran | Resveratrol 800 mg/day | 8 weeks | TG, HDL-C, LDL-C, TC, ALT, and AST | 56.48 ± 6.72, 61.10 ± 5.61 |
Chekalina NL et al. [39] | 2016 | 33/30 | CAD/Ukraine | Resveratrol 100 mg | 2 months | TG, HDL-C, LDL-C, and TC | 48–72 |
Fujitaka K et al. [40] | 2011 | 17/17 | MetS/Japan | Trans resveratrol 100 mg (Longevinex) | 3 months | TG, HDL-C, and LDL-C | 63 ± 9, 62 ± 14 |
Cicero AF et al. [41] | 2016 | 0verall 25 | Hypercholesterolemic/Italy | Resveratrol 20 mg and monacolins from M. purpureus 10 mg | 4 weeks | TG, HDL-C, LDL-C, TC, ALT, and AST | 18–70 |
Biesinger S et al. [42] | 2016 | Overall 18 | Hypertension/USA | Resveratrol 60 mg | 4 weeks | TG, HDL-C, LDL-C, and TC | 44 ± 3 |
Timmers S et al. [43] | 2011 | Overall 11 | Obesity/Netherlands | Resveratrol 150 mg | 30 days | TG | 52.5 ± 6.95, 52.5 ± 6.95 |
van der Made SM et al. [44] | 2015 | Overall 45 | Obesity/Netherlands | Resveratrol 150 mg | 4 weeks | HDL-C and TC | 61 ± 7 |
de light M et al. [45] | 2018 | Overall 13 | T2DM/Netherlands | Resveratrol 150 mg | 30 days | HDL-C, LDL-C, TC, AST, and GGT | 66 ± 7.7 |
Simental-MendÃa LE et al. [46] | 2019 | 31/31 | Dyslipidemia/México | Resveratrol 100 mg | 8 weeks | TG, HDL-C, LDL-C, and TC | 20–65 |
Fodor K et al. [47](a) | 2018 | 46/81 | Stroke/Romania | Resveratrol 100 mg + Allopathic treatment + physical rehabilitation | 48 weeks | TG, HDL-C, LDL-C, and TC | 65.03 ± 8.24, 64.78 ± 6.32 |
Fodor K et al. [47](b) | 2018 | 46/55 | Stroke/Romania | Resveratrol 200 mg + Allopathic treatment + physical rehabilitation | 48 weeks | TG, HDL-C, LDL-C, and TC | 64.52 ± 8.05, 64.78 ± 6.32 |
Mazza A et al. [48] | 2018 | 30/30 | Hypertensive and hypercholesterolemic subjects/Italy | Nutraceutical compounds capsule containing resveratrol 20 mg + standardized Mediterranean diet | 4 weeks | TG, HDL-C, LDL-C, TC, ALT, and AST | 51.5 ± 7.8, 53.0 ± 8.1 |